Artelo Biosciences’ FABP inhibitor platform featured in three presentations

Artelo Biosciences announced that three scientists each presented results from research studies demonstrating the broad therapeutic potential of Fatty Acid Binding Protein 5 – FABP5 – inhibition at the 34th Annual International Cannabinoid Research Society Symposium held June 30-July 5 in Salamanca, Spain. Myles Osborn discussed novel preclinical data showing a direct anti-tumoral effect of oral treatment with ART26.12. These data are also supportive of Artelo’s planned development of ART26.12 in chemotherapy-induced peripheral neuropathy, where ART26.12 may be able to aid in treatment of the underlying cancer, in addition to the debilitating effects of painful neuropathies. Beyond development for pain and cancer, ART26.12 has also shown the potential for therapeutic activity in dermatologic conditions. FABP5 was first identified in psoriatic lesions and there is evidence to suggest that upregulation of FABP5 contributes to the pathology of psoriasis. ART26.12, Artelo’s lead FABP inhibitor, is a selective inhibitor of FABP5 being developed as a novel, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy.